CD4 and neoplasm: Additionally, loss of ID3 leads to an increase in the CD4 Th9 phenotype, exhibiting potent antitumour immunity, and adoptive TIL therapy using tumour specific CD4 Th9 cells demonstrates potent antitumour activity (15, 38).